I see MA26 as a key for decisions. if stock will break MA26, a good position can be taken around 3.6$ All of the above at your discretion, your accepted trading rules, trading strategies and your preferred trading management. This is not a recommendation to buy or sell.
message me for details
Dynavax recently presented a company outlook for 2019 at the JP Morgan Healthcare Conference. During the presentation, CEO Eddie Gray revealed encouraging HEPISLAV-B sales for Q4 of ~$3.7M. 2018 was a big year for Dynavax's lead immuno-oncology candidate SD-101. The company has stated they are looking for a potential partner for their planned Phase III in...
Symmetrical Triangle nearly finished with it's pattern. I do not know which way it will break out, and it's likely it'll be a false breakdown if it does break bearishly. So my lean is bullish
First of all, beware of a false breakout by sharks trying to get you to go long; Basically they make it look like its breaking out of the channel but then it retracts, falls into the channel and goes to the lower end of the channel; anyways, i'm looking for the breakout; im less risk averse, so i'll be willing to take the long after two days of it remainng...
If this gaps above 21.25 I will enter this for a swing trade. If it doesn't gap up then I think I'll leave it alone. I want the gap up because I want Fridays red candle, all the people who went short on Friday to be trapped. Nothing like trading against people who are panicking!
This is an aggressive swing trade that I will be placing early Monday unless the markets look extremely bearish. I am calling this an aggressive trade because of the obvious roadblocks that it will need to overcome in order to reach the target. Also because If I am triggered into the trade and it moves in my favor I will be quickly moving my stop loss up to...
Start of final bull run ahead of 9th November FDA announcement of Heplisav approval $25-$30 price projection
Start of final bull run ahead of 9th November FDA announcement of Heplisav . $28 price projection. Final buy opportunity at $20
Lowest price buy in $20.7 ahead of the upcoming PDUFA decision. Projected price target $30
Advisory committee has voted in favour of Hepatitis-B vaccine. Now just waiting for FDA approval expected no later than November 10.
28.92% 1 month run up with 149.4% run up; it is now forming a pendant Entry: 20.95 Stop Loss: 20.30 First Profit Target: 21.90 Second 22.50
DVAX could confirm tomorrow for an upside breakout.
DVAX gapped down and then formed a flag pattern, it's tightening up towards the resistance so i'm watching for a breakout tomorrow
Technically Speaking Price is testing the 2013 low prints around $10. The first level of resistance is near the $30 level. The R/R favors the long side, in my view. I would exit on a move under $8.
Technically Speaking Price is testing the 2013 low prints around $10. The first level of resistance is near the $30 level. The R/R favors the long side, in my view. I would exit on a move under $8.